06/23/2014 - 11:57am

Vitamin D and calcium supplementation along with diet and exercise may prevent Type 2 diabetes in prediabetic individuals who have insufficient vitamin D in their bodies, a study from India suggests.

06/23/2014 - 11:48am

Almost 70% of adults with Type 1 diabetes never use their blood glucose self-monitoring devices or insulin pumps to download historical data about their blood sugar levels and insulin doses — information that likely would help them manage their disease better.

06/23/2014 - 11:41am

Soy protein supplements, which contain natural estrogens, do not reduce testosterone levels in men with Type 2 diabetes who already have borderline-low testosterone, according to a new study.

06/23/2014 - 10:51am

America’s biopharmaceutical research companies are developing 435 innovative new medicines to target 15 leading chronic conditions affecting the Medicare population, according to a new report released by the Pharmaceutical Research and Manufacturers of America last week.

06/20/2014 - 9:55am

The Food and Drug Administration has published a draft guidance document for prescription drug supply chain stakeholders as part of the agency’s implementation of the Drug Supply Chain Security Act, the National Association of Boards of Pharmacy has reported.

06/20/2014 - 9:31am

Teva has reached a settlement with Perrigo Pharmaceutical and Catalent Pharma Solutions with respect to four patents for Teva’s ProAir HFA (albuterol sulfate) Inhalation aerosol product.

06/19/2014 - 3:15pm

Walgreens has announced that it is now offering vaccinations that provide protection against pertussis (whooping cough) at all of its more than 600 stores throughout the California, as the California Department of Public Health is urging vaccination with the state reaching epidemic levels of reported whooping cough cases.

06/19/2014 - 1:48pm

The Consumer Healthcare Products Association applauded the Michigan legislature, which seeks to address the state's methamphetamine problem by targeting meth criminals.

06/19/2014 - 1:33pm

Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.